The University of Chicago Header Logo

Connection

Kenneth S. Cohen to Chicago

This is a "connection" page, showing publications Kenneth S. Cohen has written about Chicago.
Connection Strength

0.051
  1. University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL. Br J Haematol. 2018 04; 181(2):264-267.
    View in: PubMed
    Score: 0.027
  2. Identifying early dropouts from a rehabilitation program for psychiatric outpatients. Psychiatr Serv. 1995 Oct; 46(10):1076-8.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.